{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:55:39Z","timestamp":1790636139174,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01601-z","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:34:41Z","timestamp":1790588081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-9310","authenticated-orcid":false,"given":"Pouyan","family":"Shaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniyaal","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1601_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"1601_CR2","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.3390\/cancers14112588","volume":"14","author":"S Chakrabarti","year":"2022","unstructured":"Chakrabarti S, Kamgar M, Mahipal A. Systemic therapy of metastatic pancreatic adenocarcinoma: current status, challenges, and opportunities. Cancers (Basel). 2022;14:2588.","journal-title":"Cancers (Basel)"},{"key":"1601_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"1601_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"1601_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomized, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"1601_CR6","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:e2350756.","journal-title":"JAMA Netw Open"},{"key":"1601_CR7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","volume":"36","author":"DPS Sohal","year":"2018","unstructured":"Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36:2545\u201356. https:\/\/doi.org\/10.1200\/JCO.2018.78.9636.","journal-title":"J Clin Oncol"},{"key":"1601_CR8","doi-asserted-by":"publisher","first-page":"oyag085","DOI":"10.1093\/oncolo\/oyag085","volume":"31","author":"L Procaccio","year":"2026","unstructured":"Procaccio L, Giordano G, Nichetti F, et al. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Oncologist. 2026;31:oyag085.","journal-title":"Oncologist"},{"key":"1601_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"1601_CR10","doi-asserted-by":"publisher","first-page":"175883592110030","DOI":"10.1177\/17588359211003053","volume":"13","author":"K Bang","year":"2021","unstructured":"Bang K, Cheon J, Jeong JH, et al. Clinical outcomes of liposomal irinotecan plus fluorouracil\/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. Ther Adv Med Oncol. 2021;13:17588359211003053.","journal-title":"Ther Adv Med Oncol"},{"key":"1601_CR11","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1002\/cncr.35479","volume":"130","author":"A Gupta","year":"2024","unstructured":"Gupta A, De Jesus-Acosta A, Le D, Pishvaian M, Zaidi N, Zheng L, Laheru D. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: a meta-analysis of real-world evidence. Cancer. 2024;130:3734\u201344.","journal-title":"Cancer"},{"key":"1601_CR12","doi-asserted-by":"publisher","first-page":"175883592090540","DOI":"10.1177\/1758835920905408","volume":"12","author":"VHF de Jesus","year":"2020","unstructured":"de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. Ther Adv Med Oncol. 2020;12:1758835920905408.","journal-title":"Ther Adv Med Oncol"},{"key":"1601_CR13","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.","journal-title":"BMJ"},{"key":"1601_CR14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"1601_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.23.00795","volume":"42","author":"C de la Fouchardi\u00e8re","year":"2024","unstructured":"de la Fouchardi\u00e8re C, Malka D, Cropet C, et al. Gemcitabine and paclitaxel versus gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: a randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER study. J Clin Oncol. 2024;42:1055\u201366.","journal-title":"J Clin Oncol"},{"key":"1601_CR16","doi-asserted-by":"publisher","first-page":"e2249720","DOI":"10.1001\/jamanetworkopen.2022.49720","volume":"6","author":"BM Huffman","year":"2023","unstructured":"Huffman BM, Basu Mallick A, Horick NK, et al. Effect of a MUC5AC antibody (NPC-1\u00a0C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial. JAMA Netw Open. 2023;6:e2249720.","journal-title":"JAMA Netw Open"},{"key":"1601_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1601_CR18","doi-asserted-by":"publisher","first-page":"175883592110561","DOI":"10.1177\/17588359211056179","volume":"13","author":"G Huh","year":"2021","unstructured":"Huh G, Lee HS, Choi JH, et al. Gemcitabine plus nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, phase 2 trial. Ther Adv Med Oncol. 2021;13:17588359211056179.","journal-title":"Ther Adv Med Oncol"},{"key":"1601_CR19","doi-asserted-by":"crossref","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G. Meta-Analysis with R. Springer; 2015.","DOI":"10.1007\/978-3-319-21416-0"},{"key":"1601_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974\u20138.","journal-title":"J Epidemiol Community Health"},{"key":"1601_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1601_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2519\/jospt.2011.3333","volume":"41","author":"H Israel","year":"2011","unstructured":"Israel H, Richter RR. A guide to understanding meta-analysis. J Orthop Sports Phys Ther. 2011;41:496\u2013504.","journal-title":"J Orthop Sports Phys Ther"},{"key":"1601_CR23","doi-asserted-by":"publisher","first-page":"e7345","DOI":"10.1002\/cam4.7345","volume":"13","author":"G Giordano","year":"2024","unstructured":"Giordano G, Milella M, Landriscina M, et al. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Cancer Med. 2024;13:e7345.","journal-title":"Cancer Med"},{"key":"1601_CR24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/ijc.35071","volume":"155","author":"N Marschner","year":"2024","unstructured":"Marschner N, Haug N, Hegewisch-Becker S, et al. Head-to-head comparison of treatment sequences in advanced pancreatic cancer\u2014real-world data from the prospective German TPK clinical cohort study. Int J Cancer. 2024;155:1629\u201340.","journal-title":"Int J Cancer"},{"key":"1601_CR25","doi-asserted-by":"crossref","first-page":"S1301","DOI":"10.1016\/j.annonc.2023.09.925","volume":"34","author":"O Sutcuoglu","year":"2023","unstructured":"Sutcuoglu O, Do\u011fan A, Yilmaz F, \u00d6zdemir N. LBA60 Evaluation of gemcitabine-based second-line therapies after FOLFIRINOX failure. Ann Oncol. 2023;34:S1301.","journal-title":"Ann Oncol"},{"key":"1601_CR26","first-page":"156","volume":"5","author":"M Yildirim","year":"2022","unstructured":"Yildirim M, Gural Z, Kaya V. Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin\/globulin ratio in second line. J Health Sci Med. 2022;5:156\u201360.","journal-title":"J Health Sci Med"},{"key":"1601_CR27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01713-w","volume":"126","author":"S Zaibet","year":"2022","unstructured":"Zaibet S, Hautefeuille V, Auclin E, et al. Gemcitabine\u2009+\u2009nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Br J Cancer. 2022;126:1394\u2013400.","journal-title":"Br J Cancer"},{"key":"1601_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000517244","volume":"66","author":"K Hayuka","year":"2021","unstructured":"Hayuka K, Okuyama H, Murakami A, et al. Gemcitabine plus nab-paclitaxel as second-line chemotherapy following FOLFIRINOX in patients with unresectable pancreatic cancer: a single-institution, retrospective analysis. Chemotherapy. 2021;66:58\u201364.","journal-title":"Chemotherapy"},{"key":"1601_CR29","first-page":"1067","volume":"8","author":"EM Lee","year":"2021","unstructured":"Lee EM. Second line chemotherapy in patients with advanced pancreatic cancer after failure of first-line FOLFIRINOX: a retrospective analysis. Austin J Med Oncol. 2021;8:1067.","journal-title":"Austin J Med Oncol"},{"key":"1601_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000521258","volume":"45","author":"A Queck","year":"2022","unstructured":"Queck A, Elango S, Koch C, et al. Sequence therapy with FOLFIRINOX and gemcitabine\/nab-paclitaxel for patients with advanced pancreatic cancer: a monocentre retrospective cohort study. Oncol Res Treat. 2022;45:79\u201387.","journal-title":"Oncol Res Treat"},{"key":"1601_CR31","doi-asserted-by":"publisher","first-page":"175883592092342","DOI":"10.1177\/1758835920923424","volume":"12","author":"H Chae","year":"2020","unstructured":"Chae H, Jeong H, Cheon J, et al. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol. 2020;12:1758835920923424.","journal-title":"Ther Adv Med Oncol"},{"key":"1601_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s12029-018-0166-4","volume":"50","author":"DM Girardi","year":"2019","unstructured":"Girardi DM, Faria LDBB, Teixeira MC, et al. Second-line treatment for advanced pancreatic adenocarcinoma: is there a role for gemcitabine? J Gastrointest Cancer. 2019;50:860\u20136.","journal-title":"J Gastrointest Cancer"},{"key":"1601_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/jcm8060761","volume":"8","author":"N Mita","year":"2019","unstructured":"Mita N, Iwashita T, Uemura S, et al. Second-line gemcitabine plus nab-paclitaxel for patients with unresectable advanced pancreatic cancer after first-line FOLFIRINOX failure. J Clin Med. 2019;8:761.","journal-title":"J Clin Med"},{"key":"1601_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/COC.0000000000000625","volume":"42","author":"ES Tsang","year":"2019","unstructured":"Tsang ES, Spratlin J, Cheung WY, Kim CA, Kong S, Xu Y, Gill S. Real-world outcomes among patients treated with gemcitabine-based therapy post-FOLFIRINOX failure in advanced pancreatic cancer. Am J Clin Oncol. 2019;42:903\u20138.","journal-title":"Am J Clin Oncol"},{"key":"1601_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.21037\/jgo.2018.06.08","volume":"9","author":"VHF de Jesus","year":"2018","unstructured":"de Jesus VHF, Camandaroba MPG, Donadio MDS, et al. Retrospective analysis of efficacy and safety of gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX. J Gastrointest Oncol. 2018;9:806\u201319.","journal-title":"J Gastrointest Oncol"},{"key":"1601_CR36","first-page":"e451","volume":"17","author":"H Zhang","year":"2018","unstructured":"Zhang H, Kellett C, Lambert P, Kim CA. Efficacy and tolerability of second-line nab-paclitaxel and gemcitabine after failure of first-line FOLFIRINOX for advanced pancreas cancer: a single-institution experience. Clin Colorectal Cancer. 2018;17:e451\u20136.","journal-title":"Clin Colorectal Cancer"},{"key":"1601_CR37","doi-asserted-by":"publisher","first-page":"e6544","DOI":"10.1097\/MD.0000000000006544","volume":"96","author":"M Gilabert","year":"2017","unstructured":"Gilabert M, Chanez B, Rho YS, et al. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Med (Baltim). 2017;96:e6544.","journal-title":"Med (Baltim)"},{"key":"1601_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.21037\/jgo.2017.01.23","volume":"8","author":"KT Nguyen","year":"2017","unstructured":"Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, Normolle D, Bahary N. Gemcitabine\/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic\/advanced pancreatic cancer\u2014retrospective analysis of response. J Gastrointest Oncol. 2017;8:556\u201365.","journal-title":"J Gastrointest Oncol"},{"key":"1601_CR39","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.3892\/ol.2017.6061","volume":"13","author":"M Sarabi","year":"2017","unstructured":"Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with FOLFIRINOX for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917\u201324.","journal-title":"Oncol Lett"},{"key":"1601_CR40","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.dld.2017.02.007","volume":"49","author":"J Viaud","year":"2017","unstructured":"Viaud J, Brac C, Artru P, et al. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: a retrospective study. Dig Liver Dis. 2017;49:692\u20136.","journal-title":"Dig Liver Dis"},{"key":"1601_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/fon.16.16","volume":"12","author":"C Caparello","year":"2016","unstructured":"Caparello C, Vivaldi C, Fornaro L, et al. Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Future Oncol. 2016;12:901\u20138.","journal-title":"Future Oncol"},{"key":"1601_CR42","first-page":"511","volume":"6","author":"A da Rocha Lino","year":"2015","unstructured":"da Rocha Lino A, Abrah\u00e3o CM, Brand\u00e3o RM, et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol. 2015;6:511\u20135.","journal-title":"J Gastrointest Oncol"},{"key":"1601_CR43","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423\u20139.","journal-title":"J Clin Oncol"},{"key":"1601_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","volume":"17","author":"C Nevala-Plagemann","year":"2020","unstructured":"Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"1601_CR45","doi-asserted-by":"publisher","first-page":"175883592211195","DOI":"10.1177\/17588359221119539","volume":"14","author":"JW Chun","year":"2022","unstructured":"Chun JW, Woo SM, Lee SH, et al. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol. 2022;14:17588359221119539.","journal-title":"Ther Adv Med Oncol"},{"key":"1601_CR46","unstructured":"National Comprehensive Cancer Network. (2023) NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2023."},{"key":"1601_CR47","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.21037\/jgo-20-569","volume":"12","author":"JE Rogers","year":"2021","unstructured":"Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, et al. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021;12:2268\u201374.","journal-title":"J Gastrointest Oncol"},{"key":"1601_CR48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2605555.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01601-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01601-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01601-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:39Z","timestamp":1790633019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01601-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01601-z","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a systematic review and meta-analysis of previously published, de-identified aggregate data and no ethical approval is required for this study type.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve primary collection of data from human participants; all data were obtained from previously published sources.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"227"}}